GGACK is a specific and potent Factor X (factor Xa) inhibitor, reported to decrease creatine kinase and amylase activity. Reports indicate that GGACK strongly inhibits uPA (urokinase)-induced plasmin generation and acts as an anticoagulant. GGACK is an inhibitor of Factor IX, Factor VII and Trypsin.
1. Oethinger, M.D. and Seifried, E. 1990. Thromb. Haemost. 64: 402-406. PMID: 1710833 2. Ge, M., et al. 1992. J. Clin. Invest. 90: 2508-2516. PMID: 1281836 3. Kebabian, P.R. and Henkin, J. 1992. Thromb. Res. 65: 401-407. PMID: 1631804 4. Lyon, M.E., et al. 1999. Clin. Chim. Acta. 280: 91-99. PMID: 10090527
Soluble in water (50 mg/ml).
Store at -20° C
urokinase: IC50 = <1 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
bvseo_sdk, java_sdk, bvseo-3.2.0
CLOUD, getContent, 164ms
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
Lyon et alLyon et al. (PubMed ID 10090527) found that the protease inhibitor, GGACK, showed anticoagulative effects resulting from the decrease creatine kinase and amylase activity. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn